Search Results 731-740 of 18372 for alopecia

1. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas - Mayo Clinic

   All treatment-related toxicity resolved to Grade 1 or baseline (alopecia excepted);; ANC ≥ 1,500/µL;; Platelets ≥ 100,000/µL;; Hgb ≥ 9.0 g/dL (in the ...

2. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

   Any unresolved toxicity ≥ Grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to Grade 2. Plasmapheresis within 7 days prior ...

3. Mayo Clinic Q and A: Cold cap therapy can reduce hair loss caused by chemotherapy

   DEAR MAYO CLINIC: How effective is cold cap therapy in preventing hair loss in people undergoing chemotherapy treatments? Are there any risks?

4. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other non-clinically significant adverse events. - Any of the ...

5. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   ... alopecia and oxaliplatin induced neurotoxicity ≤ grade 2; Albumin levels > 2.5; Any of the following: Pregnant women; Nursing women; Men or women of ...

6. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. Note: If subjects ...

7. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   Acute effects of any prior therapy resolved to baseline severity or to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 (except for alopecia, ...

8. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

9. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

10. Massage Therapy at Mayo Clinic

    An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20170394.